Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $2.3 million.

  • Iradimed's Accounts Payables rose 6661.2% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 6661.2%. This contributed to the annual value of $1.9 million for FY2024, which is 211.7% up from last year.
  • According to the latest figures from Q3 2025, Iradimed's Accounts Payables is $2.3 million, which was up 6661.2% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's Accounts Payables ranged from a high of $2.8 million in Q3 2023 and a low of $618217.0 during Q1 2021
  • Over the past 5 years, Iradimed's median Accounts Payables value was $1.4 million (recorded in 2024), while the average stood at $1.5 million.
  • Per our database at Business Quant, Iradimed's Accounts Payables surged by 21042.7% in 2023 and then crashed by 5606.79% in 2024.
  • Quarter analysis of 5 years shows Iradimed's Accounts Payables stood at $782903.0 in 2021, then surged by 129.83% to $1.8 million in 2022, then rose by 3.21% to $1.9 million in 2023, then increased by 2.12% to $1.9 million in 2024, then rose by 23.05% to $2.3 million in 2025.
  • Its Accounts Payables was $2.3 million in Q3 2025, compared to $1.9 million in Q2 2025 and $2.6 million in Q1 2025.